Characterization of airflow properties of the mometasone furoate dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 102s Year: 2001
Comparative efficacy and safety of mometasone furoate dry powder inhaler and budesonide Turbuhaler(R) Source: Eur Respir J 2001; 17: 1332-1333 Year: 2001
Assessment of the defined daily dose for mometasone furoate dry powder inhaler in persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
A superior improvement in lung function in patients with moderate persistent asthma is seen with mometasone furoate 200 μg b.i.d delivered by dry powder inhaler compared with beclomethasone dipropionate 168 μg Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Comparison of mometasone furoate dry powder inhaler 400 mcg once daily in the evening with fluticasone propionate metered dose inhaler 250 mcg twice daily in asthma patients previously maintained on fluticasone propionate Source: Eur Respir J 2003; 22: Suppl. 45, 34s Year: 2003
Effects of mometasone furoate dry powder inhaler administered once-daily in the evening on symptom control in mild to moderate asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003
Clinical meaning and trials to reduce daily residual fluticasone propionate dry powder via Diskhaler® Source: Eur Respir J 2004; 24: Suppl. 48, 283s Year: 2004
The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
The effects of fluticasone propionate/salmeterole 50/100 μg bid in children with asthma versus beclometasone propionate 200 μg BD and fluticasone propionate 100 μg bid dry powder inhaletors Source: Eur Respir J 2004; 24: Suppl. 48, 378s Year: 2004
Effects of one year of treatment with mometasone furoate metered dose inhaler (MF-MDI) on growth in children with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 378s Year: 2004
Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS) Source: Eur Respir J 2004; 24: Suppl. 48, 164s Year: 2004
Variable lipophilicity of budesonide: Comparison with fluticasone propionate, mometasone furoate, and ciclesonide Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Formoterol: a new pMDI CFC free formulation. cumulative dose safety versus a dry powder Source: Eur Respir J 2003; 22: Suppl. 45, 473s Year: 2003
Aerodynamic characteristics of dry powder inhaler (DPI) single-dose combination of budesonide with formoterol in vitro study validation Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs) Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Higher cellular retention and activity after pulse exposure by budesonide (BUD) than fluticasone propionate (FP) and mometasone furoate (MF) Source: Eur Respir J 2001; 18: Suppl. 33, 158s Year: 2001
Mometasone furoate delivered via Breezhaler and Twisthaler in patients with asthma Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019
In-vitro product performance of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) delivered from a dry powder inhaler (DPI) using the Electronic Lung (EL) to replicate patient inhalation profiles Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies Year: 2019
Budesonide is better retained in airway tissue than fluticasone propionate and mometasone furoate due to the formation of lipophilic, slowly hydrolyzed budesonide esters Source: Eur Respir J 2003; 22: Suppl. 45, 281s Year: 2003
Variability of budesonide (BUD) fine particle dose (FPD) delivered through two multiple dose dry powder inhalers (MDPI) Source: Eur Respir J 2004; 24: Suppl. 48, 582s Year: 2004